CollPlant Biotechnologies Files August 2024 6-K Report
Ticker: CLGN · Form: 6-K · Filed: Aug 20, 2024 · CIK: 1631487
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
TL;DR
CollPlant filed its August 6-K, confirming it's a foreign private issuer filing 20-F. All systems go.
AI Summary
CollPlant Biotechnologies Ltd. filed a Form 6-K on August 20, 2024, reporting on its activities for the month of August 2024. The filing is a report of a foreign private issuer and indicates that the company files annual reports under Form 20-F. The company's principal executive office is located in Rehovot, Israel.
Why It Matters
This filing provides an update on CollPlant's ongoing operations and regulatory compliance as a foreign private issuer, which is important for investors tracking the company's status.
Risk Assessment
Risk Level: low — This filing is a routine operational report and does not contain significant new financial or strategic information that would inherently increase risk.
Key Players & Entities
- CollPlant Biotechnologies Ltd. (company) — Registrant
- August 20, 2024 (date) — Filing Date
- Rehovot, Israel (location) — Principal Executive Office
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Filing Type
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K is to report on the activities of CollPlant Biotechnologies Ltd. for the month of August 2024 as a foreign private issuer.
What is CollPlant Biotechnologies Ltd.'s filing status regarding annual reports?
CollPlant Biotechnologies Ltd. files its annual reports under cover of Form 20-F.
Where is CollPlant Biotechnologies Ltd.'s principal executive office located?
CollPlant Biotechnologies Ltd.'s principal executive office is located at 4 Oppenheimer St, Weizmann Science Park, Rehovot 7670104, Israel.
What is the Commission File Number for CollPlant Biotechnologies Ltd.?
The Commission File Number for CollPlant Biotechnologies Ltd. is 001-38370.
When was the filing submitted to the SEC?
This filing was submitted to the SEC on August 20, 2024.
Filing Stats: 414 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2024-08-20 07:11:21
Filing Documents
- ea0211600-6k_collplant.htm (6-K) — 17KB
- ea021160001ex99-1_collplant.htm (EX-99.1) — 127KB
- ea021160001ex99-2_collplant.htm (EX-99.2) — 367KB
- ea021160001ex99-3_collplant.htm (EX-99.3) — 87KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-070906.txt ( ) — 3193KB
- clgn-20240630.xsd (EX-101.SCH) — 32KB
- clgn-20240630_cal.xml (EX-101.CAL) — 27KB
- clgn-20240630_def.xml (EX-101.DEF) — 152KB
- clgn-20240630_lab.xml (EX-101.LAB) — 288KB
- clgn-20240630_pre.xml (EX-101.PRE) — 160KB
- ea0211600-6k_collplant_htm.xml (XML) — 339KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. COLLPLANT BIOTECHNOLOGIES LTD. Date: August 20, 2024 By: /s/ Eran Rotem Name: Eran Rotem Title: Deputy CEO and Chief Financial Officer 2